Navigation Links
BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
Date:6/23/2011

programs."

Mr. Bienaime continued, "The new facility in Shanbally also diversifies our manufacturing risk and provides us with an attractive business environment.  The facility is state-of-the-art, utilizing disposable technology and flexibly designed and will allow us to run either fed batch or perfusion processes.  This gives us tremendous latitude for the types of products that can be produced at the plant and allows us to focus efforts on the technical transfer of our next commercial product into the facility."

Barry O'Leary, Chief Executive of the Irish Investment and Development Agency (IDA Ireland), welcomed the investment, saying, "This is a strategically important development for BioMarin as it is the first time the company has placed internal biopharmaceutical production activities outside of the U.S. This is the next phase in BioMarin's expansion into Ireland's life sciences industry, following the establishment of an international supply chain and logistics presence in Dublin earlier this year. The decision to acquire the Shanbally plant is a significant endorsement of Ireland's wealth of talent and expertise and it is hoped that this investment will create over 100 high quality jobs in the next five years."

Mr. O'Leary continued, "Ireland has a long, successful track record of attracting significant pharmaceutical investment from multinationals. We have now established Ireland as the second largest development and manufacturing location in the world for biopharmaceuticals, after the U.S.  I am delighted to welcome BioMarin, a leading global biopharmaceutical company to Ireland and look forward to working closely with the company as it develops its operations here."

Conference Call DetailsBioMarin will host a conference call and webcast to discuss the Shanbally acquisition today, Thursday, June 23, at 9:30 a.m. ET. This event can be accessed on the investor section of the BioMarin website at

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. BioMarin to Present at the William Blair Growth Stock Conference
2. BioMarin to Present at the Jefferies Global Healthcare Conference
3. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
4. BioMarin Announces First Quarter 2011 Financial Results
5. BioMarin to Present at the Deutsche Bank Healthcare Conference
6. BioMarin to Present at the Barclays Global Healthcare Conference
7. BioMarin to Present at the Cowen Health Care Conference
8. BioMarin to Present at the Citi Global Healthcare Conference
9. BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
10. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
11. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... -- The new 13-valent pneumococcal conjugate vaccine (PCV13) appears ... prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), ... Vaccine. The U.S. Food and Drug Administration ... series of trials. These trials found that PCV13, which ... the previously used PCV7, did not increase the risk ...
(Date:5/22/2013)... , 22. Mai 2013 Kepner-Tregoe ... Beratung, gab heute bekannt, dass der Veteran ... , zum Hauptgeschäftsführer ernannt wurde. Geraghty,s ... Industriebereich wo er zahlreiche Führungspositionen bei Fertigungsunternehmen ... Baxter an, der als Kepner-Tregoe Hauptgeschäftsführer gedient ...
(Date:5/22/2013)... May 22, 2013  MGT Capital Investments, Inc. (NYSE ... at the Second Annual Marcum LLP MicroCap Conference on ... City at the Grand Hyatt Hotel.  ... Officer, will update investors and answer questions. ... presentation is scheduled to begin at 9:30 a.m. EDT.  ...
Breaking Medicine Technology:Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer 2Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 4
... The bio-pharmaceutical marketplace - and the Oncology therapeutic ... new medicines and technologies create valuable market opportunities. ... organizations with new Oncology products are scrutinizing their ... Commercial executives in the Oncology therapeutic area make ...
... 28 bioMerieux - a world leader in the ... announced the U.S. launch of chromID MRSA, a simple ... product recently received FDA 510(k) clearance for the detection ... high-morbidity healthcare-associated infections (HAI) in U.S. hospitals.(1) The current ...
Cached Medicine Technology:Educating the Marketplace to Support Successful Oncology Product Launches 2bioMerieux Adds Methicillin-resistant Staphylococcus aureus (MRSA) Screening Tool to its Arsenal 2bioMerieux Adds Methicillin-resistant Staphylococcus aureus (MRSA) Screening Tool to its Arsenal 3bioMerieux Adds Methicillin-resistant Staphylococcus aureus (MRSA) Screening Tool to its Arsenal 4
(Date:5/22/2013)... 2013 Spinal Elements, an innovative ... in Carlsbad to 3115 Melrose Drive, Suite 200, ... company’s continued and projected growth and has expanded ... feet to over 40,000 square feet. , ... indicated, “Our investment in these state-of-the-art facilities will ...
(Date:5/22/2013)... Lawrenceville, NJ and Los Angeles, CA (PRWEB) May 22, ... chairman of the board, The J. M. Smucker Company, ... GS1 Lifetime Achievement Awards yesterday at the GS1 General ... Los Angeles, California. Mr. Smucker and Mr. Wegman were ... adoption of GS1 Standards - the most broadly used ...
(Date:5/22/2013)... -- Children who are physically, sexually or emotionally abused ... in life, a new review suggests. British researchers ... to be obese as adults. They concluded that child ... for obesity. "We found that being maltreated as ... adult life," study author Dr. Andrea Danese, a child ...
(Date:5/22/2013)... p53 turns off cancer. However, when existing drugs boost p53, only ... study published in the journal Cell Reports shows how: ... more of the protein p21 than the protein PUMA; tumors that ... the current study shows a handful of genes that control this ... mutated cancer genes. Tumors turn it off and then they can ...
(Date:5/22/2013)... May 22, 2013 The new 13-valent pneumococcal conjugate ... previous version used prior to 2010, the 7-valent pneumococcal ... published today in Vaccine . , The U.S. ... in 2010 after a series of trials. These trials ... of pneumococcal types than the previously used PCV7, did ...
Breaking Medicine News(10 mins):Health News:Spinal Elements®, Inc. Relocates Corporate Headquarters in Carlsbad 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 3Health News:Abused Children at Risk for Obesity as Adults: Study 2Health News:Study details genes that control whether tumors adapt or die when faced with p53 activating drugs 2Health News:Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine 2
... Inc. (Amex:,ULU) announced today that Ronald A. Ahrens has ... Mr. Ahrens has been an advisor to Merck ... of Merck Consumer Healthcare Group Worldwide.,He had previously served ... From 1985 to 1990 Mr. Ahrens was Consumer,Group President, ...
... 23 The American Society of,Transplantation (AST) recently ... Award, to Richard N. Fine, M.D. at the,American ... a,senior investigator whose lifelong work has advanced the ... the field and the,AST have been broad and ...
... clot-busting tPA, researchers say , , MONDAY, June 23 (HealthDay ... boost stroke patients, survival, new research suggests. , Gleevec, ... as chronic myelogenous leukemia (CML), will be tested to ... the side effects of the clot-dissolving drug tissue plasminogen ...
... and Public Health Experts to Raise Public ... Awareness Via Mobile Media, ... HIV testing is getting out to the general public, thanks to,the ... most reliable wireless voice and data network,announced today its continued effort ...
... 23 Boston Scientific,Corporation (NYSE: BSX ) today ... will help service veterans and the active armed forces,better ... has recently,passed the Veterans Mental Health Improvements Act, which ... originally introduced,by Senator Daniel Akaka (D-HI). The bill calls ...
... Therapeutic Vaccines for Infectious ... Diseases, ... on emerging understanding of the human immune system,today announced the closing of ... Partners, The Column Group and Versant,Ventures. The Column Group initially incubated the ...
Cached Medicine News:Health News:ULURU Inc. Announces the Appointment of Ronald A. Ahrens to the Board of Directors 2Health News:AST Awards Richard N. Fine, M.D. 2008 Ernest Hodge Distinguished Achievement Award 2Health News:Cancer Drug Gleevec Could Fight Stroke 2Health News:Cancer Drug Gleevec Could Fight Stroke 3Health News:Verizon Wireless Continues Support of National HIV Testing Awareness Campaign 2Health News:Verizon Wireless Continues Support of National HIV Testing Awareness Campaign 3Health News:Boston Scientific Welcomes Progress on Pain Care Legislation 2Health News:Boston Scientific Welcomes Progress on Pain Care Legislation 3Health News:Boston Scientific Welcomes Progress on Pain Care Legislation 4Health News:Immune Design Announces $18 Million Series A Financing 2Health News:Immune Design Announces $18 Million Series A Financing 3
... Oximeter with SAC (Serial Autocorrelation) Technology uses ... extract SpO 2 , pulse strength, and ... This cost-effective compact monitor incorporates clinical, ... features, and a data log or trend ...
... Autocorr Plus, the fourth in the ... pulse oximeter/ECG/Respiration Monitor, with 3 or ... oximetry with SAC (Serial Autocorrelation) technology, ... screen display provides two user configurable ...
... The BCI 3180 Pulse Oximeter is a ... SpO 2 pulse rate and pulse ... adult. This AC or battery powered ... low alarm limits and up to 30 ...
... ReZoom intraocular lens is a second-generation refractive ... with greater independence from glasses than monofocal ... a range of vision that monfocals cannot ... technology distributes light over five optic zones ...
Medicine Products: